Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ethicon seals Omrix deal

This article was originally published in The Gray Sheet

Executive Summary

Wound management division of J&J unit gains exclusive North American marketing and distribution rights for Crosseal fibrin sealant from Belgian firm Omrix Biopharmaceuticals, adding to an exclusive European pact from June 2003. The first non-bovine sealant to launch in the U.S., Crosseal originally was cleared via biologics license application in March 2003 for use as an adjunct to hemostasis in liver surgery patients. Ethicon notes the device has a triple lumen delivery mechanism that does not mix the human thrombin and biological active component until they reach the tip - a feature that may prevent clogging seen in other sealants. Baxter's Tisseel uses aprotinin, a protein derived from cow lungs, and is Crosseal's chief competitor (1"The Gray Sheet" July 28, 2003, p. 16)...

You may also be interested in...

Non-Bovine Fibrin Sealant Launches In U.S.; Red Cross To Distribute Crosseal

American Red Cross Plasma Services' three U.S. distributors will ship Omrix Biopharmaceuticals' Crosseal fibrin sealant to liver surgeons throughout the summer

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts